Altimmune (NASDAQ:ALT) Coverage Initiated by Analysts at Barclays

Barclays assumed coverage on shares of Altimmune (NASDAQ:ALT) in a report issued on Tuesday, Marketbeat reports. The brokerage issued an overweight rating and a $20.00 target price on the stock.

Other research analysts have also recently issued research reports about the company. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of Altimmune in a report on Monday, October 20th. Citizens Jmp decreased their price target on Altimmune from $15.00 to $14.00 and set a “market outperform” rating for the company in a research report on Friday, November 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Altimmune in a research note on Monday, December 29th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Altimmune in a research note on Wednesday, November 12th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.17.

Altimmune Price Performance

ALT stock traded up $0.04 during trading hours on Tuesday, hitting $5.16. 1,219,404 shares of the stock traded hands, compared to its average volume of 6,507,034. The stock has a 50-day simple moving average of $4.64 and a 200 day simple moving average of $4.14. The company has a market cap of $538.71 million, a P/E ratio of -4.85 and a beta of 0.04. Altimmune has a one year low of $2.90 and a one year high of $7.73. The company has a current ratio of 17.18, a quick ratio of 17.18 and a debt-to-equity ratio of 0.08.

Altimmune (NASDAQ:ALT) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.08. Altimmune had a negative net margin of 419,575.00% and a negative return on equity of 54.79%. The company had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.00 million. Equities analysts forecast that Altimmune will post -1.35 earnings per share for the current year.

Insider Buying and Selling

In other Altimmune news, Director John Gill acquired 12,500 shares of the firm’s stock in a transaction that occurred on Tuesday, December 23rd. The stock was purchased at an average cost of $4.10 per share, for a total transaction of $51,250.00. Following the completion of the acquisition, the director owned 12,500 shares of the company’s stock, valued at approximately $51,250. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Jerome Benedict Durso bought 12,500 shares of the stock in a transaction on Monday, December 22nd. The shares were acquired at an average cost of $4.13 per share, for a total transaction of $51,625.00. Following the completion of the transaction, the director directly owned 12,500 shares of the company’s stock, valued at approximately $51,625. The trade was a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired 30,527 shares of company stock valued at $125,278 over the last quarter. Corporate insiders own 4.40% of the company’s stock.

Institutional Investors Weigh In On Altimmune

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Victory Capital Management Inc. acquired a new position in Altimmune during the 3rd quarter valued at $38,000. BNP Paribas Financial Markets raised its position in shares of Altimmune by 108.5% during the second quarter. BNP Paribas Financial Markets now owns 10,095 shares of the company’s stock valued at $39,000 after buying an additional 5,253 shares during the last quarter. Kingswood Wealth Advisors LLC bought a new stake in shares of Altimmune in the second quarter valued at about $40,000. Prudential Financial Inc. bought a new stake in shares of Altimmune in the second quarter valued at about $43,000. Finally, Sequoia Financial Advisors LLC acquired a new stake in Altimmune during the third quarter worth about $46,000. Institutional investors and hedge funds own 78.05% of the company’s stock.

Altimmune Company Profile

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.